“GlaxoSmithKline Plc (GSK) will begin a hostile $2.6 billion tender offer this week for Human Genome Sciences Inc. after the U.S. company, its partner on the Benlysta drug for lupus, rebuffed a takeover approach.
If you enjoy the content at iBankCoin, please follow us on TwitterRelated Articles
$MSFT Pink Slips 18k Jobs
July 17, 2014
$GS & $JPM Manage to Beat Net Profit Estimates
July 15, 2014